Literature DB >> 32377963

Tracheostomy in patients with acute respiratory distress syndrome is not related to quality of life, symptoms of psychiatric disorders or return-to-work: the prospective DACAPO cohort study.

Sebastian Blecha1, Magdalena Brandl2, Florian Zeman3, Frank Dodoo-Schittko2, Susanne Brandstetter2,4, Christian Karagiannidis5, Thomas Bein6, Christian Apfelbacher2,7.   

Abstract

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a life-threatening condition that often requires prolonged mechanical ventilation. Tracheostomy is a common procedure with some risks, on the other hand with potential advantages over orotracheal intubation in critically ill patients. This study investigated the association of tracheostomy with health-related quality of life (HRQoL), symptoms of psychiatric disorders and return-to-work of ARDS survivors.
METHODS: Data were collected in the context of the prospective observational German-wide DACAPO study. Clinical and demographic patient data and treatment characteristics were obtained from the participating intensive care units (ICU). HRQoL and return-to-work were assessed using patient-reported questionnaires 3, 6 and 12 months after ICU discharge. HRQoL was measured with the Physical and Mental Component Scale of the Short-Form 12 Questionnaire (PCS-12, MCS-12). The prevalence of psychiatric symptoms (depression and post-traumatic stress disorder [PTSD]) was assessed using the Patient Health Questionnaire-9 and the Post-Traumatic Stress Syndrome-14. Physician-diagnosed anxiety and obsessive-compulsive disorder were recorded by patient self-report in the follow-up questionnaires. The associations of tracheostomy with HRQoL, psychiatric symptoms and return-to-work after 12 months were investigated by means of multivariable linear and logistic regression models.
RESULTS: Primary 877 ARDS patients (mean ± standard deviation: 54 ± 16 years, 68% male) survived and were discharged from ICU. Out of these patients, 478 (54.5%) were tracheotomised during ICU treatment. After 12 months, patient-reported outcomes could be analysed of 388 (44.2%) respondents, 205 with tracheostomy and 183 without. One year after ICU discharge, tracheostomy showed no significant association with physical or mental health-related quality of life (PCS-12: - 0.73 [- 3.96, 2.51]; MCS-12: - 0.71 [- 4.92, 3.49]), symptoms of psychiatric disorders (depression: 0.10 [- 1.43, 1.64]; PTSD: 3.31 [- 1.81, 8.43]; anxiety: 1.26 [0.41, 3.86]; obsessive-compulsive disorder: 0.59 [0.05, 6.68]) or return-to-work (0.71 [0.31, 1.64]) in the multivariable analysis (OR [95%-CI]).
CONCLUSIONS: Up to 1 year after ICU discharge, neither HRQoL nor symptoms of psychiatric disorders nor return-to-work was affected by tracheostomy. Trial registration NCT02637011 (ClinicalTrials.gov, Registered 15 December 2015, retrospectively registered).

Entities:  

Keywords:  ARDS; Health-related quality of life; Intensive care; Return-to-work; Tracheostomy

Year:  2020        PMID: 32377963     DOI: 10.1186/s13613-020-00671-x

Source DB:  PubMed          Journal:  Ann Intensive Care        ISSN: 2110-5820            Impact factor:   6.925


  3 in total

1.  Association of analgosedation with psychiatric symptoms and health-related quality of life in ARDS survivors: Post hoc analyses of the DACAPO study.

Authors:  Sebastian Blecha; Florian Zeman; Magdalena Rohr; Frank Dodoo-Schittko; Susanne Brandstetter; Christian Karagiannidis; Christian Apfelbacher; Thomas Bein
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  Characterisation and outcomes of ARDS secondary to pneumonia in patients with and without SARS-CoV-2: a single-centre experience.

Authors:  Rahul Y Mahida; Minesh Chotalia; Joseph Alderman; Chhaya Patel; Amber Hayden; Ruchi Desai; Emily Beesley; Louise E Crowley; Marina Soltan; Mansoor Bangash; Dhruv Parekh; Jaimin Patel; David R Thickett
Journal:  BMJ Open Respir Res       Date:  2020-11

3.  Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.

Authors:  Syed Shahzad Hasan; Toby Capstick; Raees Ahmed; Chia Siang Kow; Faizan Mazhar; Hamid A Merchant; Syed Tabish Razi Zaidi
Journal:  Expert Rev Respir Med       Date:  2020-09-29       Impact factor: 3.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.